MabCure Inc. (OTCBB: MBCI) Working on Therapies For Three Cancers
MabCure’s strategy is to first concentrate on deadly, fast-growing cancers where demand is instant, huge and growing. It’s a sound, realistic business objective.
(EMAILWIRE.COM, November 04, 2009 ) New York, NY - Keros Client Developing Antibodies For Three Cancers
Ovarian Cancer is Almost Always Detected When It’s Too Late - Forbes magazine Calls This, “Scandalous” and They’re Right.
Last year 22,430 new cases were diagnosed and 15,280 women died from this illness. 1 in 7 women during their lifetime will get it. The biggest problem with this illness is late diagnosis. Most are found to have it when doctors can’t stop it. Tragically, it’s one of the easiest to halt—IF you detect it in advance. Until now, thanks to MabCure, there has been NO diagnostic test for ovarian cancer. Between 61 and 100 million women pay $25 to have a pap smear to detect illness, a highly unreliable test. This adds up to $1.5 billion a year spent on ineffective healthcare measures, a market MabCure could capture with an effective detection method.
Prostate Cancer Touched 218,890 People In 2008. PSA Tests are Shockingly Bad - Even the Inventor of the Test Admits It!
Prostate cancer is another senseless way to lose your health. Catch this one early and it too is no problem. In 2008, 218,890 cases were diagnosed. Sadly, 27,050 perished from it. It’s the second leading cause of death among men. According to the organization Cancer Facts, “Every man over the age of 45 is at risk for it…” Most men rely on the famous PSA test. That’s a major mistake because it is so incredibly unreliable. Medical Research News reports, “The PSA test is now all but useless for predicting prostate cancer risk.” Even the doctor who invented it, Dr. Thomas Stamey now says that it may be useless in detecting prostate cancer.
According to The American Cancer Society, it’s estimated that more than 40 million PSA tests are performed worldwide each year. Since the cost per PSA test is $40 to $80, the world market for these tests ranges from $1.6 to $3.2 billion annually. Another huge market segment MabCure could capture with a reliable testing method based on their breakthrough discovery.
Melanoma Has a 99% Survival Rate IF It’s Found Early - 8,110 People Should Have Been Saved Last Year.
Melanoma is the most serious form of skin cancer. It suddenly appears without warning. The American Academy of Dermatology says, “melanoma is rising at an alarming rate.” One American passes away from it every hour. Unfortunately, it’s the most common form of cancer in the country. As the Mayo Clinic says, “If detected early, melanoma has a 99% survival rate…” Last year, 108,230 cases were diagnosed.
MabCure’s strategy is to first concentrate on deadly, fast-growing cancers where demand is instant, huge and growing. It’s a sound, realistic business objective.
Time Magazine Reports
Time Magazine said that, “We are in the midst of a complete and profound change in our development of cancer treatments…This was all a dream five years ago…doctors will be given tools for detecting the earliest stages of many cancers – in some cases when they are only a few cells strong – and suppressing them before they have a chance to progress to malignancy…”
MabCure Inc. currently trades at about $1.00 per share on the Over the Counter Bulletin Board, and developments are happening fast!
Disclosure: All material herein was prepared by Keros Capital Inc. (Keros) based upon information believed to be reliable. The information contained herein is not guaranteed by Keros to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Keros is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.keroscapital.com or mentioned herein. Keros has been compensated seven thousand five hundred dollars for this advertising effort. Keros may receive additional compensation for future advertisements. Keros affiliates, officers, directors and employees may own shares and may buy and sell additional shares of the company mentioned herein and may profit in the event those shares rise in value. Keros will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market. Copyright 2007 by Keros Capital. All rights reserved. This publication or part thereof may not be duplicated or reprinted without the written permission of the Publisher. Facsimile including photocopy(s) is strictly forbidden, except for facsimile correspondence between Keros Capital. If this publication contravenes any securities laws and/or regulations, the securities regulations of the country will prevail. In this event, this publication must be discarded immediately. Anyone not wishing to receive future Keros Capital Investor Reports should email us at opt-out@keroscapital.com
Ovarian Cancer is Almost Always Detected When It’s Too Late - Forbes magazine Calls This, “Scandalous” and They’re Right.
Last year 22,430 new cases were diagnosed and 15,280 women died from this illness. 1 in 7 women during their lifetime will get it. The biggest problem with this illness is late diagnosis. Most are found to have it when doctors can’t stop it. Tragically, it’s one of the easiest to halt—IF you detect it in advance. Until now, thanks to MabCure, there has been NO diagnostic test for ovarian cancer. Between 61 and 100 million women pay $25 to have a pap smear to detect illness, a highly unreliable test. This adds up to $1.5 billion a year spent on ineffective healthcare measures, a market MabCure could capture with an effective detection method.
Prostate Cancer Touched 218,890 People In 2008. PSA Tests are Shockingly Bad - Even the Inventor of the Test Admits It!
Prostate cancer is another senseless way to lose your health. Catch this one early and it too is no problem. In 2008, 218,890 cases were diagnosed. Sadly, 27,050 perished from it. It’s the second leading cause of death among men. According to the organization Cancer Facts, “Every man over the age of 45 is at risk for it…” Most men rely on the famous PSA test. That’s a major mistake because it is so incredibly unreliable. Medical Research News reports, “The PSA test is now all but useless for predicting prostate cancer risk.” Even the doctor who invented it, Dr. Thomas Stamey now says that it may be useless in detecting prostate cancer.
According to The American Cancer Society, it’s estimated that more than 40 million PSA tests are performed worldwide each year. Since the cost per PSA test is $40 to $80, the world market for these tests ranges from $1.6 to $3.2 billion annually. Another huge market segment MabCure could capture with a reliable testing method based on their breakthrough discovery.
Melanoma Has a 99% Survival Rate IF It’s Found Early - 8,110 People Should Have Been Saved Last Year.
Melanoma is the most serious form of skin cancer. It suddenly appears without warning. The American Academy of Dermatology says, “melanoma is rising at an alarming rate.” One American passes away from it every hour. Unfortunately, it’s the most common form of cancer in the country. As the Mayo Clinic says, “If detected early, melanoma has a 99% survival rate…” Last year, 108,230 cases were diagnosed.
MabCure’s strategy is to first concentrate on deadly, fast-growing cancers where demand is instant, huge and growing. It’s a sound, realistic business objective.
Time Magazine Reports
Time Magazine said that, “We are in the midst of a complete and profound change in our development of cancer treatments…This was all a dream five years ago…doctors will be given tools for detecting the earliest stages of many cancers – in some cases when they are only a few cells strong – and suppressing them before they have a chance to progress to malignancy…”
MabCure Inc. currently trades at about $1.00 per share on the Over the Counter Bulletin Board, and developments are happening fast!
Disclosure: All material herein was prepared by Keros Capital Inc. (Keros) based upon information believed to be reliable. The information contained herein is not guaranteed by Keros to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Keros is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.keroscapital.com or mentioned herein. Keros has been compensated seven thousand five hundred dollars for this advertising effort. Keros may receive additional compensation for future advertisements. Keros affiliates, officers, directors and employees may own shares and may buy and sell additional shares of the company mentioned herein and may profit in the event those shares rise in value. Keros will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market. Copyright 2007 by Keros Capital. All rights reserved. This publication or part thereof may not be duplicated or reprinted without the written permission of the Publisher. Facsimile including photocopy(s) is strictly forbidden, except for facsimile correspondence between Keros Capital. If this publication contravenes any securities laws and/or regulations, the securities regulations of the country will prevail. In this event, this publication must be discarded immediately. Anyone not wishing to receive future Keros Capital Investor Reports should email us at opt-out@keroscapital.com
|
FREE Penny Stock Alerts!
Get Amazing Penny Stock ALERTS Totally FREE Click This Link NOW. GetRichPicks.com How to buy Penny Stocks Learn the Skills, Make the Trades, Earn a Fortune! 100% Free to try. Chartpoppers.com Stop Being Fooled By "Penny Stock Picks" Subscribe To The #1 Rated MicroCap Stock Newsletter. MicroCapster.com Analyst Penny Stock Picks Visit StockSource.us for explosive stock picks, free stock research and trading tools www.StockSource.us Your text Ads here! Ads are only $575 per month. Ads are placed same day. Contac Us Emailwire.com/contact.php |